Wednesday, September 30, 2026 | Time TBC
Multiple sclerosis (MS) remains one of the most complex neurological diseases to monitor and manage. While MRI and clinical assessment remain central to patient care, there is growing interest in blood-based biomarkers that may provide additional insight into disease activity and neuroaxonal injury. Neurofilament light chain (NfL) has emerged as one of the most widely studied biomarkers in this area, with increasing evidence supporting its role in multiple sclerosis research and evaluation.
This webinar, presented by Professor Tobias Sejbæk, will explore the scientific evidence behind NfL, its potential role alongside existing approaches to disease monitoring, and the practical considerations involved in evaluating, validating, and implementing NfL testing in laboratory and clinical settings. Attendees will gain insight into the analytical considerations that influence assay confidence, the growing body of real-world evidence supporting NfL evaluation, and broader neurological applications of this emerging biomarker.
Key learning objectives:
- Describe how blood-based NfL may provide complementary information alongside MRI and how it is associated with neuroaxonal injury and disease activity in published studies.
- Identify key considerations for evaluating NfL testing in laboratory and clinical settings, including factors influencing interpretation and use alongside clinical and imaging data.
- Recognize the role of NfL as a general marker of axonal injury and its potential applications beyond relapsing multiple sclerosis in neurological research.
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
The following planners and faculty reported relevant financial relationship(s):
- Professor Tobias Sejbæk, MD, PhD
- Relevant financial relationships disclosed with Siemens Healthineers
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
- Instruction level: Intermediate
- Accreditation: P.A.C.E.® eligible
Registration is required to secure your place. If you register but can't attend live, you will receive a link to the on-demand recording once it becomes available.
Who should attend?
This event is perfect for:
- Clinical laboratorians
- Neurology-focused laboratory professionals
- Clinical researchers working in neurology
- Laboratory directors and managers
- Hospital and health-system decision-makers
- Stakeholders evaluating the adoption of novel biomarkers
- Professionals involved in assay implementation and laboratory workflow optimization
- Current approaches to monitoring and assessing multiple sclerosis.
- The biological significance of NfL as a marker of neuroaxonal injury.
- Published evidence linking NfL with disease activity, progression, and clinical outcomes in multiple sclerosis.
- How NfL may provide complementary information alongside MRI and clinical assessment.
- Analytical performance considerations, assay confidence, and factors influencing result interpretation.
- Key considerations for evaluating and validating NfL testing in laboratory settings.
- Real-world evidence and experiences associated with implementing NfL into clinical and laboratory workflows.
- Current and emerging applications of NfL across neurological research and disease management.
- Future directions for biomarker-driven approaches to neurological disease management.
Presenters
Professor Tobias Sejbæk, MD, PhD
Clinical Associate Professor, Head of Research,
IRS - Esbjerg and Grindsted Hospital
Professor Tobias Sejbaek, MD, PhD is an academic neurologist and researcher with expertise in multiple sclerosis and neurobiomarkers. He is affiliated with the Department of Biochemistry and Molecular Genetics at the School of Medicine, Université Clermont Auvergne, and serves as Head of Research at Esbjerg Hospital, University Hospital of Southern Denmark, and University of Southern Denmark (SDU). Professor Sejbaek is a former Vice President and Board Member of the Danish Neurological Association (2019–2023) and was a member of the 2024 ECTRIMS Organizing Committee.
Lucy Lawrence
Science Editor
SelectScience